Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells

Saved in:

Bibliographic Details
Main Authors:	M. Strnad, L. Havlia, P. Binarova, V. Kryscaron, J. Hanuscaron, V. Siglerova, L. Boumlgre, E. Heberle-Bors
Format:	Article
Language:	English
Published:	Wiley 2001-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/tsw.2001.229
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
by: M. Strnad, et al.
Published: (2001-01-01)

Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.
by: Ana L Alessandri, et al.
Published: (2011-01-01)

Efficient activation of reconstructed rat embryos by cyclin-dependent kinase inhibitors.
by: Robin L Webb, et al.
Published: (2010-03-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
by: Jonatan Kaszubski, et al.
Published: (2024-11-01)

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01)

Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01)

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume
by: Bediz Kurt İnci, et al.
Published: (2024-09-01)

CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01)

Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products.
by: Abhijit Debnath, et al.
Published: (2025-01-01)

Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
by: Abhijit Debnath, et al.
Published: (2025-01-01)

Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
by: Shun-Hua Chen, et al.
Published: (2025-06-01)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
by: Stanley Madu Nwabudike, et al.
Published: (2018-01-01)

Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer
by: Minyoung Lee, et al.
Published: (2025-07-01)

Current view of the inhibitor protein cyclin-dependent kinase р16, р27 and their role in the cell cycle
by: A. K. Aleksandrova, et al.
Published: (2016-02-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
by: Razia Rahman, et al.
Published: (2025-05-01)

Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5.
by: Ammar H Hawasli, et al.
Published: (2009-06-01)

Knockout of cyclin-dependent kinases 8 and 19 leads to depletion of cyclin C and suppresses spermatogenesis and male fertility in mice
by: Alexandra V Bruter, et al.
Published: (2025-04-01)

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01)

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
by: Ilenia Pellarin, et al.
Published: (2025-01-01)

THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS
by: S. L. Pavlinsky, et al.
Published: (2017-09-01)

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01)

Anti colorectal cancer activity and in silico studies of novel pyridine nortopsentin analog as cyclin dependent kinase 6 inhibitor
by: Heba Abdelmegeed, et al.
Published: (2024-11-01)

Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in Curative Breast Cancer Patients Induced Pneumonitis: A Case Report
by: Pei-Yu Hou
Published: (2025-04-01)

Olomoucine II, New Effective CDK Inhibitor with Strong Cytotoxic Properties
by: R. Lenobel, et al.
Published: (2001-01-01)

Autoimmune Bullous Disorders induced by Cyclin-Dependent Kinase 4/6 inhibitors – first case series from the EADV Task Force “Dermatology for Cancer Patients”
by: A. Ortiz Brugués, et al.
Published: (2024-01-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
by: Pınar Kubilay Tolunay, et al.
Published: (2024-11-01)

Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei.
by: Séverine Monnerat, et al.
Published: (2013-01-01)

Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers
by: Petra Minarikova, et al.
Published: (2016-01-01)

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
by: Isah Adamu Danbala, et al.
Published: (2025-06-01)

Association between cyclin-dependent kinase 4/6 inhibitors and nephrotoxicity in patients with breast cancer: A Systematic Review and meta-analysis
by: Jiayong Cui, et al.
Published: (2024-12-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

Overexpression of cyclin‐dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance
by: Han‐Jie Zhang, et al.
Published: (2021-11-01)

Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro
by: Yi Wu, et al.
Published: (2025-07-01)

Targeting the cyclin-dependent kinase family in anticancer drug discovery: From computational to experimental studies
by: Priyanka Solanki, et al.
Published: (2024-12-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

MiR-192–5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3
by: Biswajit Sahoo, et al.
Published: (2025-04-01)

Design, Molecular Docking, Synthesis, Characterization and Preliminary Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
by: Yousef Sabah Ali, et al.
Published: (2025-01-01)